Mesa Laboratories (MLAB)
(Delayed Data from NSDQ)
$118.79 USD
-2.00 (-1.66%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $118.32 -0.47 (-0.40%) 5:18 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.79 USD
-2.00 (-1.66%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $118.32 -0.47 (-0.40%) 5:18 PM ET
1-Strong Buy of 5 1
B Value A Growth B Momentum A VGM
Zacks News
Mesa Labs (MLAB) Q2 Earnings Top Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 0.58% and -1.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mesa Labs (MLAB) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 7.18% and 2.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Mesa Labs (MLAB) Q1 Earnings Expected to Decline
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mesa Labs (MLAB) Misses Q3 Earnings Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -1.08% and 3.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session
by Zacks Equity Research
Neovasc (NVCN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Edwards Lifesciences (EW) in Focus: Stock Moves 7.7% Higher
by Zacks Equity Research
Edwards Lifesciences (EW) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Mesa Laboratories (MLAB) Enters Oversold Territory
by Zacks Equity Research
Mesa Laboratories, Inc. (MLAB) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Mesa Laboratories Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Mesa Laboratories has been struggling lately, but the selling pressure may be coming to an end soon.
New Strong Sell Stocks for November 21st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
The Zacks Analyst Blog Highlights: PRA Health Sciences, Mesa Laboratories, ConforMIS, Check-Cap and Streamline Health Solutions
by Zacks Equity Research
The Zacks Analyst Blog Highlights: PRA Health Sciences, Mesa Laboratories, ConforMIS, Check-Cap and Streamline Health Solutions
5 MedTech Stocks to Buy Before Q3 Earnings
by Zacks Equity Research
The Q3 earnings season is just around the corner for the political hotspot MedTech space.
5 Medtech Stocks to Steer Clear of Amid Political Chaos
by Zacks Equity Research
In view of the current political scenario and unfavorable metrics, these five MedTech stocks are best avoided for now.
Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View
by Zacks Equity Research
Illumina (ILMN) delivers an impressive Q2 on strong uptake of sequencing consumables and microarrays and continued adoption of NovaSeq platform. A raised guidance buoys optimism.
DaVita (DVA) Beats Earnings and Revenue Estimates in Q2
by Zacks Equity Research
DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.
VWR Corp (VWR) Beats Earnings & Revenue Estimates in Q2
by Zacks Equity Research
VWR Corp (VWR) reported an impressive Q2 and is presently awaiting a merger with Avantor.
IDEXX Laboratories (IDXX) Q2 Earnings & Revenues Top, View Up
by Zacks Equity Research
IDEXX Laboratories (IDXX) rides high on strength across all segments in Q2 with significant contributions from the Companion Animal Group business. Moreover, a raised guidance buoys optimism.
Hill-Rom Holdings (HRC) Beats Q3 Earnings, Misses Revenues
by Zacks Equity Research
Hill-Rom Holdings (HRC) rides high on international growth and product innovation.
NuVasive (NUVA) Beats on Q2 Earnings, Retains 2017 View
by Zacks Equity Research
NuVasive (NUVA) rides high on continued growth in international business in Q2. Also, the company has worked on revamping its organizational structure.
Omnicell (OMCL) Earnings Meet, Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell (OMCL) benefited from high XT revenues and strength in IV Solutions in Q2.
Abaxis (ABAX) Misses Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Despite Abaxis' lackluster performance in the fiscal first quarter, its new marketing strategies and recent launches buoy optimism.
GNC Holdings (GNC) Tops Q2 Earnings, Misses Sales Estimates
by Zacks Equity Research
Sluggish performance by the U.S. & Canada international and manufacturing/wholesale segments marred second-quarter results for GNC Holdings (GNC).
Align Technology (ALGN) Beats on Q2 Earnings and Revenues
by Zacks Equity Research
Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.
QIAGEN (QGEN) Beats on Earnings & Sales in Q2, Raises View
by Zacks Equity Research
QIAGEN (QGEN) continues to bank on the Molecular Diagnostics space for growth.